A057880 Stock Overview
PHC Co.,Ltd. engages in the medical drug, bio, medical, and distribution businesses in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PHC Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,740.00 |
| 52 Week High | ₩3,510.00 |
| 52 Week Low | ₩927.00 |
| Beta | -0.17 |
| 11 Month Change | 0% |
| 3 Month Change | 2.66% |
| 1 Year Change | 20.00% |
| 33 Year Change | -23.01% |
| 5 Year Change | -40.51% |
| Change since IPO | -50.10% |
Recent News & Updates
Shareholder Returns
| A057880 | KR Consumer Durables | KR Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | -0.7% |
| 1Y | 20.0% | -9.9% | -4.1% |
Return vs Industry: A057880 exceeded the KR Consumer Durables industry which returned 0.3% over the past year.
Return vs Market: A057880 exceeded the KR Market which returned 8% over the past year.
Price Volatility
| A057880 volatility | |
|---|---|
| A057880 Average Weekly Movement | n/a |
| Consumer Durables Industry Average Movement | 4.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A057880 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A057880's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 71 | In-hwan Choi | www.philosyshealthcare.co.kr |
PHC Co.,Ltd. engages in the medical drug, bio, medical, and distribution businesses in South Korea and internationally. The company develops Nex Bio drugs for the treatment of hemophilia A, anemia, hormone, and macular degeneration diseases.
PHC Co.,Ltd. Fundamentals Summary
| A057880 fundamental statistics | |
|---|---|
| Market cap | ₩205.82b |
| Earnings (TTM) | -₩38.82b |
| Revenue (TTM) | ₩28.31b |
7.3x
P/S Ratio-5.3x
P/E RatioIs A057880 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A057880 income statement (TTM) | |
|---|---|
| Revenue | ₩28.31b |
| Cost of Revenue | ₩25.47b |
| Gross Profit | ₩2.84b |
| Other Expenses | ₩41.66b |
| Earnings | -₩38.82b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -328.22 |
| Gross Margin | 10.02% |
| Net Profit Margin | -137.15% |
| Debt/Equity Ratio | 0% |
How did A057880 perform over the long term?
See historical performance and comparison